← Back to Search

Dietary Supplement

GlaucoCetin for Glaucoma

N/A
Waitlist Available
Led By Natasha N Kolomeyer, MD
Research Sponsored by Wills Eye
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 20 minute questionnaires during a 6 month period
Awards & highlights

Summary

This trial is testing a daily supplement called GlaucoCetin, which aims to help people with open angle glaucoma. The supplement is designed to protect and support the nerve cells in the eye that are crucial for vision. Researchers want to see if taking GlaucoCetin over several months can improve vision and overall quality of life for these patients.

Who is the study for?
This trial is for people aged 40-80 with open-angle glaucoma, controlled eye pressure, and good visual acuity. Participants must have specific types of visual field defects but no other significant eye diseases or recent surgeries. They shouldn't be on certain medications like nitroglycerin or anti-seizure drugs, nor should they have uncontrolled blood pressure or diabetes.
What is being tested?
The study tests GlaucoCetin, a medical food designed to protect optic nerve cells in glaucoma patients against a placebo over six months. Patients are randomly chosen to receive either the treatment or placebo to see if there's an improvement in vision.
What are the potential side effects?
Potential side effects aren't detailed here but could relate to ingredients in GlaucoCetin such as Curcumin and Ginkgo Biloba which may cause digestive upset or allergic reactions in some individuals.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~20 minute questionnaires during a 6 month period
This trial's timeline: 3 weeks for screening, Varies for treatment, and 20 minute questionnaires during a 6 month period for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Visual Field Mean Deviation
Secondary study objectives
Perceived Quality of Life Improvement
Perceived Quality of Life Improvement measured by National Eye Institute Visual Function Questionnaire 25 (NEI VFQ-25)

Trial Design

4Treatment groups
Active Control
Placebo Group
Group I: GlaucoCetin Peripheral GroupActive Control1 Intervention
Primary Open Angle Glaucoma participants who meet inclusion exclusion criteria with peripheral visual field loss will be randomly assigned GlaucoCetin, a medical food in capsule form.
Group II: GlaucoCetin Central GroupActive Control1 Intervention
Primary Open Angle Glaucoma participants who meet inclusion exclusion criteria with central visual field loss will be randomly assigned GlaucoCetin, a medical food in capsule form.
Group III: Placebo Peripheral GroupPlacebo Group1 Intervention
Primary Open Angle Glaucoma participants who meet inclusion exclusion criteria with peripheral visual field loss will be randomly assigned a placebo, with no nutritional value, in capsule form.
Group IV: Placebo Central GroupPlacebo Group1 Intervention
Primary Open Angle Glaucoma participants who meet inclusion exclusion criteria with central visual field loss will be randomly assigned a placebo, with no nutritional value, in capsule form.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for glaucoma primarily aim to reduce intraocular pressure (IOP) to prevent damage to the optic nerve. Medications such as prostaglandin analogs increase the outflow of aqueous humor, while beta-blockers and carbonic anhydrase inhibitors reduce its production. Neuroprotective strategies, like those being studied in GlaucoCetin, focus on supporting and protecting optic nerve cells from degeneration. This is crucial for glaucoma patients as preserving the health of optic nerve cells can slow disease progression and help maintain vision.

Find a Location

Who is running the clinical trial?

Guardian Health Sciences, Inc.UNKNOWN
Wills EyeLead Sponsor
80 Previous Clinical Trials
15,336 Total Patients Enrolled
49 Trials studying Glaucoma
9,896 Patients Enrolled for Glaucoma
Natasha N Kolomeyer, MDPrincipal InvestigatorWills Eye Hospital

Media Library

GlaucoCetin (Dietary Supplement) Clinical Trial Eligibility Overview. Trial Name: NCT04784234 — N/A
Glaucoma Research Study Groups: GlaucoCetin Peripheral Group, Placebo Peripheral Group, GlaucoCetin Central Group, Placebo Central Group
Glaucoma Clinical Trial 2023: GlaucoCetin Highlights & Side Effects. Trial Name: NCT04784234 — N/A
GlaucoCetin (Dietary Supplement) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04784234 — N/A
~21 spots leftby Oct 2025